Markets:

Overview

News

Currencies

International

Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.24 -0.71 (-4.45%)

Streaming Delayed Price Updated: 12:36 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Banned Merger ↗

July 27, 2021

Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood.

Via Talk Markets

Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021

July 26, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

July 16, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs

June 30, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)

June 25, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Reconsidered Boom ↗

June 22, 2021

The US markets tried to repeat the big rise from yesterday, and appears to have succeeded.

Via Talk Markets

The First Day Of Summer And Prime Day ↗

June 21, 2021

The bull is back in business today.

Via Talk Markets

Two Rate Hikes In 2023 ↗

June 16, 2021

This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard.

Via Talk Markets

Topics Economy

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

June 14, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Wednesday News And Catch-Up ↗

June 09, 2021

Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA.

Via Talk Markets

Topics Stocks

Aurinia Announces Results of the 2021 Annual General Meeting

June 07, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress

June 07, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Fan Hit ↗

June 03, 2021

The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares.

Via Talk Markets

Unusual Options Activity Insight: Aurinia Pharmaceuticals ↗

June 03, 2021

Aurinia Pharmaceuticals (NASDAQ:AUPH) shares experienced unusual options activity on Thursday. The stock price moved down to $13.6 following the option alert. Sentiment: BEARISH...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements ↗

June 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

May 27, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients ↗

May 21, 2021

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in...

Via Benzinga

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis

May 20, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

2 Grossly Undervalued Biotech Stocks That Could Double Your Money ↗

May 19, 2021

Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.

Via The Motley Fool

Another Tough Day For Markets ↗

May 17, 2021

The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.”

Via Talk Markets

Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences

May 14, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Heavy Global Erosion ↗

May 11, 2021

It is an everything-down day. Even the news is down because commenters are being careful.

Via Talk Markets

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

May 10, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 10, 2021

Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT)....

Via Benzinga

Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet ↗

May 10, 2021

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with...

Via Benzinga

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet

May 10, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

70 Biggest Movers From Friday ↗

May 10, 2021

Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.